Ruxolitinib treatment improves muscle mass in patients with myelofibrosis

Ann Hematol. 2021 Apr;100(4):1105-1106. doi: 10.1007/s00277-020-04243-8. Epub 2020 Sep 1.

Authors

Marko Lucijanic¹, Davor Galusic², Ena Soric³, Martina Sedinic³, Marta Cubela⁴, Renata Huzjan Korunic^{4

5}, Vlatko Pejsa^{3

5}, Rajko Kusec^{3

5}

Affiliations

¹ Hematology Department, University Hospital Dubrava, Av. Gojka Suska 6, 10000, Zagreb, Croatia. markolucijanic@yahoo.com.
² Hematology Department, University Hospital of Split, Split, Croatia.
³ Hematology Department, University Hospital Dubrava, Av. Gojka Suska 6, 10000, Zagreb, Croatia.
⁴ Radiology Department, University Hospital Dubrava, Zagreb, Croatia.
⁵ School of Medicine, University of Zagreb, Zagreb, Croatia.

PMID: 32870367
DOI: 10.1007/s00277-020-04243-8

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Cohort Studies
Female
Humans
Male
Muscles / drug effects*
Nitriles
Primary Myelofibrosis / diagnostic imaging
Primary Myelofibrosis / drug therapy*
Primary Myelofibrosis / etiology
Pyrazoles / therapeutic use*
Pyrimidines
Retrospective Studies
Statistics, Nonparametric
Tomography, X-Ray Computed
Treatment Outcome

Substances

Nitriles
Pyrazoles
Pyrimidines
ruxolitinib